Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Merck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis

Merck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis

  • June 22, 2026

Merck is making advances in the lucrative ulcerative colitis field with the key prize of its $11 billion buyout from several years ago.

Leave A Comment

Fields (*) Mark are Required